Skip to content

Welcome to Discover Pharma! Today is : November 5, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

clinical development

  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Allucent adds strategy leaders to expand therapeutic expertise

    Allucent has appointed new therapeutic strategy leaders across key disease [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Aravax adds allergy specialists to board as peanut therapy advances

    Aravax has appointed two senior industry figures to its board [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Hansa Biopharma’s BLA for imlifidase accepted by FDA

    Hansa Biopharma’s Biologics License Application (BLA) for imlifidase has been [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Lario receives $2.4M from MJFF and Wellcome to expand neuronal calcium channel research in CNS disorders

    Lario Therapeutics awarded $2.4M by The Michael J. Fox Foundation [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Polaryx therapeutics selects contract research organization for SOTERIA phase 2 basket trial

    Polaryx Therapeutics, Inc has selected a leading contract research organization [...]

    May 5, 2026
  • Biotech & Pharma Business,Medical devices,Therapeutic Areas

    Neupulse secures £3M to advance neurotherapeutic device for Tourette Syndrome

    Neupulse, a UK-based neurotherapeutics company, has raised £3 million in [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Insilico Medicine and CMS announce AI-powered drug discovery collaborations in CNS and autoimmune diseases

    Insilico Medicine and China Medical System Holdings Limited (CMS) have [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Manufacturing & Supply Chain,Therapeutic Areas

    CellProthera acquires full rights to transendocardial catheter from Celyad Oncology

    CellProthera has acquired full rights to the transendocardial catheter originally [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Oryzon appoints Rolando Gutierrez-Esteinou as chief medical officer for CNS programs

    Oryzon Genomics has appointed Rolando Gutierrez-Esteinou, as chief medical officer [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development

    Evinova and Bristol Myers Squibb collaborate on AI-driven clinical trial optimisation

    Evinova and Bristol Myers Squibb have entered a strategic collaboration [...]

    May 5, 2026
Previous345Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • AltruBio reports early ulcerative colitis data for ALTB-268
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Survey finds patient groups are split on involvement in drug pricing
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics
  • Johnson & Johnson reports three-year Crohn’s disease results for guselkumab
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top